Clinical Trials
21 trialsNCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT05564052 2025-10-07
VEGA
Janssen Research & Development, LLC
Phase 2 Completed
NCT01183949 2024-08-02
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT02352558 2023-11-14
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT00722137 2018-07-12
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Takeda
Phase 3 Completed
NCT00931918 2017-01-11
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Takeda
Phase 2 Completed
NCT00407303 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00871546 2015-08-07
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT01902862 2014-04-01
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
Janssen-Cilag G.m.b.H
Phase 2 Terminated
NCT00791011 2014-03-05
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Amgen
Phase 1 Completed
NCT01040871 2014-01-13
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00715208 2013-04-29
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00850499 2012-12-12
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00312845 2012-06-25
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00608907 2012-01-30
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00636792 2012-01-13
VERTICAL
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00063713 2008-02-11
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00085696 2008-02-11
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed